Results 31 to 40 of about 142,658 (312)

Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease

open access: yesFrontiers in Medicine, 2023
Background and objectivesPreclinical interstitial lung disease (pILD) may represent the early stages of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Dandan Chai   +7 more
doaj   +1 more source

MRI of the lung (3/3)-current applications and future perspectives [PDF]

open access: yes, 2011
BackgroundMRI of the lung is recommended in a number of clinical indications. Having a non-radiation alternative is particularly attractive in children and young subjects, or pregnant women.MethodsProvided there is sufficient expertise, magnetic ...
M. Both   +30 more
core   +1 more source

Comorbidities in unclassifiable interstitial lung disease

open access: yesRespiratory Research, 2022
Background Comorbidities are common in interstitial lung diseases (ILD) and have an important association with survival, but the frequency and prognostic impact of comorbidities in unclassifiable interstitial lung disease (uILD) remains elusive. We aimed
Thomas Skovhus Prior   +6 more
doaj   +1 more source

The Role of Cutibacterium acnes in Sarcoidosis: From Antigen to Treatable Trait?

open access: yesMicroorganisms, 2022
Cutibacterium acnes (C. acnes, formerly Propionibacterium acnes) is considered to be a non-pathogenic resident of the human skin, as well as mucosal surfaces. However, it also has been demonstrated that C.
Raisa Kraaijvanger, Marcel Veltkamp
doaj   +1 more source

Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis

open access: yesDiagnostics, 2021
Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate ...
Volodymyr Gavrysyuk   +6 more
doaj   +1 more source

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

open access: yesEuropean Respiratory Review, 2019
Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines.
Bridget F. Collins, Ganesh Raghu
doaj   +1 more source

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

open access: yesMedical Sciences, 2018
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias.
Estrella Fernández Fabrellas   +3 more
doaj   +1 more source

Interstitial lung diseases in children

open access: yesLa Presse Médicale, 2020
Interstitial lung disease (ILD) in children (chILD) is a heterogeneous group of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. The pathogenesis of the various chILD is complex and the diseases share common features of inflammatory and fibrotic changes of the lung parenchyma that impair gas exchanges.
Nadia, Nathan   +4 more
openaire   +3 more sources

YouTube-videos for patient education in lymphangioleiomyomatosis?

open access: yesRespiratory Research, 2022
Background The Internet is commonly used by patients to acquire health information. To date, no studies have evaluated the quality of information available on YouTube regarding lymphangioleiomyomatosis (LAM).
Finn M. Wilkens   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy